Myocet liposomal (previously Myocet)
doxorubicin · CHEPLAPHARM Arzneimittel GmbH
AUTHORISED IN THE EUWhat Myocet liposomal (previously Myocet) is used for
Myocet liposomal, in combination with cyclophosphamide, is indicated for the first-line treatment of metastatic breast cancer in adult women.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Myocet liposomal (previously Myocet)
- Active substance
- doxorubicin
- Disease area
- Breast Neoplasms
- Medicine group
- Antineoplastic agents
- ATC code
- L01DB01
- Marketing authorisation holder
- CHEPLAPHARM Arzneimittel GmbH
- Authorised in the EU since
- 2000
Official information
In the USA
Same active substance: Doxil
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Myocet liposomal (previously Myocet) used for?
Myocet liposomal, in combination with cyclophosphamide, is indicated for the first-line treatment of metastatic breast cancer in adult women.
What is the active substance in Myocet liposomal (previously Myocet)?
Myocet liposomal (previously Myocet) contains doxorubicin.
Who makes Myocet liposomal (previously Myocet)?
The EU marketing authorisation holder is CHEPLAPHARM Arzneimittel GmbH.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU